NCT07499050

A Study of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

An Investigator- and Participant-Blind, Randomized, Placebo-Controlled, Parallel-Group, Phase I Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Doses of Orally Administered RO7795081 in Otherwise Healthy Chinese Adult Participants With Obesity or Overweight

• Status: Recruiting
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Hoffmann-La Roche · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

This is an investigator- and participant-blind, randomized, placebo-controlled, parallel-group, Phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple doses of orally administered RO7795081 in otherwise healthy Chinese adult participants with obesity or overweight.

Conditions

• Healthy Volunteers
• Overweight or Obesity

Interventions

Type	Name	Description
DRUG	RO7795081	RO7795081 will be administered orally once a day.
DRUG	Placebo	Placebo will be administered orally once a day.

Timeline

• Start date: 2026-03-30
• Primary completion: 2026-12-29
• Completion: 2026-12-29
• First posted: 2026-03-30
• Last updated: 2026-04-13

Locations

2 sites across 1 country: China